State Street SPDR S&P Pharmaceuticals ETF

XPH

Market cap $327M

Not every exchange-traded fund (ETF) worth owning trades at a premium. Some of the most structurally sound funds sit quietly below the radar, offering low costs, reliable income, or sector exposure that the broader market has yet to reprice fully.

SPDR S&P Pharmaceuticals ETF ( NYSEARCA:XPH ) exists to solve a specific problem: how do you gain broad exposure to pharmaceutical companies without the concentration risk of the largest healthcare names dominating your returns?

Big Pharma delivered strong Q4 2025 results, with most companies beating revenue and EPS expectations and providing generally solid 2026 guidance. Eli Lilly solidified its leadership in obesity and diabetes, outpacing Novo Nordisk, which faces a sharp 2026 revenue decline amid fierce competition, pricing pressure, and other factors.

Designed to provide broad exposure to the Health Care ETFs category of the market, the State Street SPDR S&P Pharmaceuticals ETF (XPH) is a smart beta exchange traded fund launched on 06/19/2006.

The State Street SPDR S&P Pharmaceuticals ETF (XPH) was launched on June 19, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Pharma segment of the equity market.

Healthcare providers have a good value score, and the pharmaceuticals & biotechnology subsector has a good quality score. State Street SPDR S&P Pharmaceuticals ETF provides modified equal-weighted exposure to the pharmaceutical industry, reducing company-specific risk versus cap-weighted peers. XPH is best suited for tactical allocation or swing trading, not as a long-term core holding, given its historical underperformance.

As big pharmaceutical companies are set to finalize a deal with the U.S. government to bring down prices for some prescription drugs, another old question is coming into focus for investors: how much damage can Washington really do to Big Pharma's bottom line?

Worried about high valuations? KBE, XRT, and XPH with low P/Es and fresh momentum are three undervalued ETFs to consider as 2026 approaches.

For investors seeking momentum, State Street SPDR S&P Pharmaceuticals ETF XPH is probably on the radar. The fund just hit a 52-week high and rose 61.4% from its 52-week low price of $35.22/share.

The move marks a victory for the Trump administration's campaign to get other countries to pay more for drugs.